The Hospital for Sick Children, Toronto, longitudinal ERG study of children on vigabatrin

Documenta Ophthalmologica

Volumn 104, Issue 2, 2002, Pages 133-149

  Westall, Carol A ^a,b   Logan, William J ^c   Smith, Kim ^a   Buncic, J Raymond ^a,b   Panton, Carole M ^a   Abdolell, Mohamed ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

ERG; Pediatric; Retinal toxicity; Vigabatrin

Indexed keywords

CARBAMAZEPINE; CISAPRIDE; CLOBAZAM; CYCLOPENTOLATE; LAMOTRIGINE; NITRAZEPAM; PHENOBARBITAL; PHENYLEPHRINE; RANITIDINE; VALPROIC ACID; VIGABATRIN;

AMPLITUDE MODULATION; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTACT LENS; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; HUMAN; LONGITUDINAL STUDY; MONOTHERAPY; OSCILLATORY POTENTIAL; PHOTOPIC VISION; RETINA CONE; RETINA DISEASE; RETINA ROD; SEIZURE;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ELECTRORETINOGRAPHY; EPILEPSY; HUMANS; INFANT; LONGITUDINAL STUDIES; RETINA; VIGABATRIN;

EID: 0036215970     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014656626174     Document Type: Article

References (34)

1. Vigabatrin treatment in children
2. Vigabatrin as first line therapy in infantile spasms: Review of seven patients
3. Vigabatrin in pediatric epilepsy - An open study
4. Vigabatrin in childhood epilepsy: A 5-year follow-up study
5. Severe persistent visual field constriction associated with vigabatrin
6. Visual field defects associated with vigabatrin therapy
7. Characteristics of a unique visual field defect attributed to vigabatrin
8. Symptomatic and asymptomatic visual loss in patients taking vigabatrin
9. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction; A comparative follow-up study with patients on initial carbamazepine monotherapy and healthy controls
10. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
11. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin
12. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings
13. Visual impairment in children with epilepsy treated with vigabatrin
14. Visual field constriction is not limited to children treated with vigabatrin
15. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings
16. Outer retinal dysfunction in patients treated with vigabatrin
17. Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss
18. Longitudinal investigation of ERGs in children on vigabatrin therapy
19. Visual electrophysiological effect of a GABA transaminase blocker
20. Visual function loss from vigabatrin: Effect of stopping the drug
21. Standard for clinical electroretinography (1999 update)
22. Time course for maturation of electroretinogram response, from infancy to adulthood
23. The human suprathreshold photopic oscillatory potentials: Method of analysis and clinical application
24. Effects of anticonvulsant drugs in retinal function. Psychophysical and electrophysiological findings in patients with epilepsy
25. Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin
26. Neuropsychiatric drug effects on the visual nervous system
27. Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy
28. GABA, picrotoxin and retinal sensitivity
29. Possible role of amacrine cells in the generation of the mammalian ERG b-wave
30. Oscillatory potentials in the retina: What do they reveal
31. GABA-mediated control of transient signals in the inner retina
32. Optic nerve hypoplasia in association with brain anomalies and an abnormal electroretinogram
33. Electroretinography: Application to clinical studies of infants
34. Which ocular and neurological conditions cause disparate results in visual acuity scores recorded with VEP and teller acuity cards?